Clinical Trial

A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to demonstrate that V181 is safe and well tolerated, elicits an immune response, and reduces the frequency of virologically confirmed dengue (VCD) of any severity, due to any of the 4 dengue serotypes, regardless of dengue serostatus at baseline in children 2 to 17 years of age.
Protocol Amendment History 21 amendments
This ClinicalTrials.gov record has been amended 21 times since 2025-06-02; most recent amendment 2026-07-08.
Status change: Not Yet Recruiting → Recruiting 2025-06-11
Trial Details
NCT Number NCT07013487
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Healthy
Enrollment 12,000 participants
Start Date 2025-06-11
Primary Completion 2031-10-24 (estimated)
Study Completion 2031-10-24 (estimated)
Updated on ClinicalTrials.gov 2026-07-10